Baird said he would be a buyer on weakness of Oscar Health (OSCR) shares as the proposed HIX rule creates uncertainty. Baird maintained its Outperform rating and $28 price target on Oscar Health shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR:
- Oscar Health put volume heavy and directionally bearish
- Oscar Health accused of misusing NSA to delay payments, The Capitol Forum says
- Cautious Outlook Amid Uncertainty: Sell Rating for Oscar Health
- Oscar Health Faces Uncertainty Amid Revenue Miss and Enrollment Risks, Analyst Maintains Sell Rating
- Oscar Health Shines in 2024 Earnings Call